Severe Asthma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Severe Asthma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.

The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Severe Asthma Pipeline Report: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years.
• Severe Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others, are developing therapies for the Severe Asthma treatment
• Emerging Severe Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others are expected to have a significant impact on the Severe Asthma market in the coming years.
• In February 2022, In order to treat asthma and chronic obstructive pulmonary disease (COPD), Honeywell and AstraZeneca have formed a business agreement to create and sell next-generation respiratory inhalers that use propellants with almost no global warming potential (GWP).
• In September 2024, UK-based pharmaceutical firm GSK revealed results from two Phase III clinical trials of depemokimab in patients with severe asthma marked by elevated blood eosinophil levels, a sign of type 2 inflammation. The SWIFT-1 and SWIFT-2 trials, both double-blind and placebo-controlled, evaluated the efficacy and safety of depemokimab as an add-on therapy compared to a placebo. Both studies achieved their primary goals, showing a statistically significant reduction in the annualized rate of clinically significant asthma exacerbations over 52 weeks compared to placebo.
• In May 2024, GSK's long-acting asthma drug, the anti-IL-5 antibody Nucala (mepolizumab), successfully reached its primary endpoint in Phase III clinical trials.

Severe Asthma Overview
Severe asthma is a chronic respiratory condition characterized by persistent, difficult-to-control symptoms despite high-dose medications such as inhaled corticosteroids and bronchodilators. Individuals with severe asthma experience frequent symptoms like shortness of breath, wheezing, coughing, and tightness in the chest, and they are prone to severe asthma attacks that require medical intervention. Severe asthma can be triggered by allergens, respiratory infections, and environmental factors, and often requires more intensive treatments, including biologic therapies or oral corticosteroids, to manage symptoms and improve quality of life.

Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:
• LNR 125.38: Lanier Biotherapeutics
• BAT2606: Bio-Thera Solutions
• KN-002: Kinaset Therapeutics
• CM326: CSPC ZhongQi Pharmaceutical Technology
• FB 704A: Oneness Biotech Co., Ltd.
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• Masitinib: AB Science
• GSK3511294: GlaxoSmithKline
Severe Asthma Pipeline Therapeutics Assessment
• Severe Asthma Assessment by Product Type
• Severe Asthma By Stage and Product Type
• Severe Asthma Assessment by Route of Administration
• Severe Asthma By Stage and Route of Administration
• Severe Asthma Assessment by Molecule Type
• Severe Asthma by Stage and Molecule Type

DelveInsight's Severe Asthma Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Severe Asthma Therapeutics Market include:
Key companies developing therapies for Severe Asthma are - Genentech, Inc., GlaxoSmithKline, Kymab, Sanofi, 4D Pharma plc, AstraZeneca, Sinomab, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Cumberland Pharmaceuticals, and others.

Severe Asthma Pipeline Analysis:
The Severe Asthma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.
• Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Severe Asthma drugs and therapies
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Asthma Pipeline Market Drivers
• Increase in the prevalence of Severe Asthma, development of new and innovative treatment options for severe asthma are some of the important factors that are fueling the Severe Asthma Market.

Severe Asthma Pipeline Market Barriers
• However, high cost of asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Severe Asthma Market growth.

Scope of Severe Asthma Pipeline Drug Insight
• Coverage: Global
• Key Severe Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others
• Key Severe Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others
• Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
• Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers

Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Severe Asthma Report Introduction
2. Severe Asthma Executive Summary
3. Severe Asthma Overview
4. Severe Asthma- Analytical Perspective In-depth Commercial Assessment
5. Severe Asthma Pipeline Therapeutics
6. Severe Asthma Late Stage Products (Phase II/III)
7. Severe Asthma Mid Stage Products (Phase II)
8. Severe Asthma Early Stage Products (Phase I)
9. Severe Asthma Preclinical Stage Products
10. Severe Asthma Therapeutics Assessment
11. Severe Asthma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Severe Asthma Key Companies
14. Severe Asthma Key Products
15. Severe Asthma Unmet Needs
16 . Severe Asthma Market Drivers and Barriers
17. Severe Asthma Future Perspectives and Conclusion
18. Severe Asthma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Severe Asthma Market
DelveInsight's 'Severe Asthma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Severe Asthma Epidemiology
DelveInsight's 'Severe Asthma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.